Novo Nordisk remains a strong buy as it trades at a low 12.5x P/E ratio despite robust growth and expanding international operations, which now account for 65% of group growth. The company’s EUCAN obesity care segment grew 52% at constant exchange rates, and its oral obesity franchise outperforms competitors. Although US list price cuts are planned for 2027, net revenues are expected to remain stable due to shifts in realized net pricing and structural liabilities. Improvements in cost structure and a strong free cash flow yield of 5.9% support the view that the stock is undervalued.
Novo Nordisk maintains a Buy rating driven by strong uptake of its oral obesity drug Wegovy, which has captured 90% of the US oral obesity market with over 5 million prescriptions since launch. The company’s robust GLP-1 franchise and upcoming drug a...
Eli Lilly shows strong performance with 48% revenue growth driven by GLP-1 drugs Mounjaro and Zepbound, raising 2026 guidance significantly. Novo Nordisk struggles with pricing cuts and pipeline setbacks, keeping its stock range-bound despite solid s...
